Drug Type Small molecule drug |
Synonyms FDC-G, Nyxol/latanoprost, Phentolamine/latanoprost |
Mechanism PTGFR agonists(Prostanoid FP receptor agonists), adrenergic receptor antagonists(Adrenergic receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC26H40O5 |
InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N |
CAS Registry130209-82-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mydriasis | NDA/BLA | US | 06 Dec 2022 | |
Glaucoma | Preclinical | US | 15 Aug 2019 |